Prospective trials of implantable cardioverter defibrillators versus drugs: Are they addressing the right question?

American Journal of Cardiology

Volumn 77, Issue 10, 1996, Pages 859-863

  Josephson, Mark ^b   Nisam, Seah ^a  

^a CPI/Guidant Europe   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

CARDIOVERSION; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; EDITORIAL; ELECTROPHYSIOLOGY; HEART EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; IMPLANT; PRIORITY JOURNAL; QUALITY OF LIFE; SUDDEN DEATH;

EID: 0029945722     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89182-5     Document Type: Article

References (29)

1. Nisam S, Thomas A, Mower M, Hauser R. Identifying patients for prophylactic automatic implantabte cardioverter defibrillator therapy: status of prospective studies. Am Heart J 1991;122:607-612.
2. Bigger T. Future studies with the implantable cardioverter defibrillator. PACE 1991;14:883-889.
3. Wever E, Hauer R. Cost-effectiveness considerations: the Dutch Prospective Study of the automatic implantable cardioverter defibrillator as first-choice therapy. PACE 1992;15:690-693.
4. Mower M, Thomas A, Nisam S, Graf J. Effectiveness of implantable cardio-verter-defibrillators. Problems and progress in the design of randomized trials. J Electrocardiol 1994;26:42-50.
5. Furman S. AICD benefit. PACE 1989;12:399-400.
6. Kim S. Implantable defibrillator therapy: does it really prolong life? How can we prove it? Am J Cardiol 1993;71:1213-1218.
7. Fogoros R. The implantable defibrillator backlash. Am J Cardiol 1991; 67:1424-1427.
8. Connolly S, Yusuf S. Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: the need for randomized trials. Am J Cardiol 1992;69:959-962.
9. Sweeney M, Ruskin J. Mortality benefits and the implantable cardioverter defibrillator. Circulation 1994;89:1851-1858.
10. Fogoros R. An AVID dissent (editorial). PACE 1994;17:1707-1710.
11. Hallstrom A. Letter to the editor. PACE 1995;18:747.
12. Connolly S. An AVID dissent: commentary. PACE 1994;17:1712-1713.
13. Epstein A. AVID necessity. PACE 1994;16:1773-1775.
14. Epstein A. Reply to the editor. PACE 1994;17:262-266.
15. Zipes D. Are implantable cardioverter-defibrillators better than conventional antiarrhythmic drugs for survivors of cardiac arrest? (editorial). Circulation 1995;91:2115-2117.
16. Wever E, Hauer R, Van Capelle F, Tijssen J, Crijns H, Algra A, Wiesfeld A, Bakker P, Robles de Medina E. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-2203.
17. Greene H. Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study. Am Heart J 1994;127:1171-1178.
18. Schwartz P, Camm A, Frangin G, Janse J, Julian D, Simon P, on behalf of the EMIAT Investigators. Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial. Eur Heart J 1994;15:620-624.
19. Cairns J, Connolly J, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial pilot study. Circulation 1991;84:550-557.
20. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
21. Bocker D, Block M, Isbruch F, Wietholt D, Hammel D, Borggrefe M, Breithardt G. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol 1993;21:1638-1644.
22. Powell A, Finkelstein D, Garan H, Fuchs T, Cannom D. McGovern B. Kelly E, Vlahakes G, Torchiana D. Ruskin J. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-1092.
23. Herre J, Sauve M, Scheinman M. Long-term results of amiodarone therapy with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989;13:442-449.
24. Mason J, on behalf of the ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
25. Weinberg B, Miles W, Klein S, Bolander J, Dusman R, Stanton M, Heger J, Langefeld C, Zipes D. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 1993;125:109-120.
26. Greene H, for the CASCADE Investigators. Cardiac Arrest in Seattle: Conventional versus Amiodarone Drug Evaluation: the CASCADE study. Am J Cardiol 1991;67:578-584.
27. Akhtar M, Avitall B, Jazayeri M, Tchou P, Troup P, Sra J, Axtel K. Role of implantable cardioverter defibrillator therapy in the management of high-risk patients. Circulation 1992;85:1-131-1-139.
28. Winkle R, Mead H, Ruder M, Gaudlani V, Smith N, Buch W, Schmidt P, Shipman T. Long-term outcome with the automatic implantable cardioverter defibrillator. J Am Coll Cardiol 1989;13:1353-1361.
29. Newman D, Sauve J, Herre J, Langberg J, Lee M, Titus C, Franklin J, Scheinman M, Griffin J. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992;69:889-903.